Aurinia Receives National Corporate Visionary Award from the Lupus Foundation of America
October 12 2017 - 06:00AM
Business Wire
Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today
announced it has received this year’s National Corporate Visionary
Award from the Lupus Foundation of America. The award was presented
to Dr. Richard and Michelle Glickman and to Aurinia for its
long-term commitment to advancing treatments for lupus and lupus
nephritis. The award was presented yesterday evening during the
Foundation’s Annual Evening of Hope Gala in New York City.
“We are humbled and thrilled to accept this award,” said Dr.
Glickman. “The Foundation’s work is crucial to advancing treatments
for this disease, and I am proud of the progress Aurinia is making
to contribute to the understanding and treatment of the disease.
“Our drive to succeed is fueled by patients and their families, who
continue to inspire us as we work to make innovative therapies
available as quickly and efficiently as possible.”
About AuriniaAurinia is a clinical stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are suffering
from serious diseases with a high unmet medical need. The company
is currently developing voclosporin, an investigational drug, for
the treatment of LN. The company is headquartered in Victoria, BC
and focuses its development efforts globally.
www.auriniapharma.com.
About the Lupus Foundation of AmericaThe Lupus Foundation
of America is the only national force devoted to solving the
mystery of lupus, one of the world’s cruelest, most unpredictable
and devastating diseases, while giving caring support to those who
suffer from its brutal impact. Through a comprehensive program of
research, education, and advocacy, we lead the fight to improve the
quality of life for all people affected by lupus. Learn more about
the Lupus Foundation of America at lupus.org. For the latest news
and updates, follow us on Twitter and Facebook.
We seek safe harbor.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171012005466/en/
Investors:Celia EconomidesVP, Corporate & Public
Affairsceconomides@auriniapharma.comorMedia:Christopher
Hippolyte, 212-364-0458Christopher.hippolyte@inventivhealth.com